Imaging Working Group
Standardization of Imaging Modalities in ATTR and AL Amyloidosis
Goals
To standardize imaging modalities in transthyretin (ATTR) and light chain (AL)amyloidosis to improve use in care management and drug development.
Rationale
- Imaging modalities have advanced to enable detection of amyloid deposits in involved organs, and to assess comorbidities, disease stage/prognosis, and treatment response in ATTR and AL amyloidosis.
- Standardization of each imaging modality and establishing test-retest criteria and meaningful changes in patients with cardiac amyloidosis is necessary to further develop imaging endpoints for use within clinical trials.
Members
Adam Castaño
BridgeBio
Ashutosh Wechalekar
National Amyloidosis Centre, University College of London
August Hofling
FDA
Jamie Zigterman
Amyloidosis Research Consortium
Jeremy Slivnick
The University of Chicago Medicine
Marianna Fontana
National Amyloidosis Centre, University College of London
Monica Stanley
FDA
Prem Soman
University of Pittsburgh Medical Center (UPMC)
Rick Ruberg
Boston Medical Center
Rodney Falk
Brigham and Women's Hospital
Spencer Guthrie
Attralus
Sue-Jane Wang
FDA
Teresia Moller
Life Molecular Imaging